Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772863 | 1.00 | MAPT (0.49) | MAPTTSHRLMNAHTTNLRP3 | |
| SCHEMBL17238107 | 0.82 | TDP1 (0.41) | MAPTHTTMEN1KMT2ANPC1 | |
| SCHEMBL17238087 | 0.82 | ALDH1A1 (0.40) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL17238086 | 0.82 | ALDH1A1 (0.40) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL17238109 | 0.82 | TDP1 (0.41) | MAPTHTTMEN1KMT2ANPC1 | |
| SCHEMBL21313129 | 0.81 | ALDH1A1 (0.42) | MAPTTSHRLMNAMEN1KMT2A | |
| SCHEMBL21313127 | 0.81 | ALDH1A1 (0.42) | MAPTTSHRLMNAMEN1KMT2A | |
| SCHEMBL17237985 | 0.80 | MEN1 (0.49) | MAPTTSHRLMNAHTTMEN1 | |
| SCHEMBL17237983 | 0.80 | MEN1 (0.49) | MAPTTSHRLMNAHTTMEN1 | |
| Potassium Ion SCHEMBL23930585 | 0.79 | ALDH1A1 (0.40) | MAPTLMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | ABBVIE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008152223-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | MAPT 4555/4885TSHR 2314/4885LMNA 4708/4885 |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | MAPT 4542/4885TSHR 4144/4885LMNA 642/4885 |
| US-10112911-B2 | Substituted cyanoguanidines as oral anti-virals | RNGTT, GMPS, RNMT | MAPT 4484/4885TSHR 4419/4885LMNA 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.